– USA, CA – DIMERx, Inc., a late-stage clinical biopharmaceutical company developing covalently bonded dimer therapeutics, today announced the appointment of Dr. Sergio Traversa (PharmD) to its Board as an Independent Director to its Board of Directors, effective June 25, 2025.
About Dr. Sergio Traversa
Dr. Sergio Traversa serves as CEO of Relmada Therapeutics (Nasdaq: RLMD), a clinical-stage biotechnology company focused on developing transformative therapies for oncology-related and central nervous system conditions, where he has led the company through the advancement of multiple clinical-stage programs and financing events.
Dr. Sergio Traversa brings over 25 years of experience in the healthcare sector across the United States and Europe, spanning pharmaceutical leadership, strategic advisory, and investment. He has held senior roles at leading pharmaceutical companies, including Eli Lilly and Johnson & Johnson, and served in investment and advisory positions at firms such as Mehta and Isaly, Merlin BioMed, and Rx Capital.
Dr. Sergio Traversa was also the co-founder and CEO of Medeor Inc., a pharmaceutical company spun out of Cornell University. He currently serves as a strategic advisor and independent board member for several emerging biopharmaceutical companies, leveraging his broad expertise to guide innovation, development, and financing strategies.
About DIMERx, Inc.
DIMERx is a clinical-stage biopharmaceutical company pioneering a proprietary dimer technology platform to develop novel chemical entities for high-impact, underserved medical conditions. Co-founded by Gregory Beyer, Harvinder Dhani, and Nikhilesh Singh, PhD, the company also collaborates closely on clinical strategy with Maurizio Fava, MD, Chair, Mass General Brigham Academic Medical Centers Psychiatry Department.
The company’s lead asset, DMX-101, is a covalently modified, chemically stable, halogen-free buprenorphine dimer (CAS No: 1820753-68-1) that acts peripherally at the source to provide non-addictive pain relief. DMX-101 is in phase 2 clinical development for chronic lower back pain. Across Phase 1 and Phase 2a studies involving over 400 human subjects and patients, it has demonstrated a favorable safety profile—including pancreatic safety—and clear analgesic benefits.
DIMERx’s second program, DMX-201, is a covalently linked dimer of arginine and agmatine—a next-generation nitric oxide (NO) donor being developed for conditions involving endothelial dysfunction, such as vaso-occlusive crisis (VOC) pain in sickle cell disease, where treatment options remain dominated by centrally acting opioids.
For more information: https://www.dimerx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.